BURNING ROCK BIOTECH LTD-ADR (BNR)

Company Profile

Burning Rock Biotech Ltd. engages in the investment of medical fields. The company is headquartered in Guangzhou, Guangdong and currently employs 1,138 full-time employees. The company went IPO on 2020-06-12. The firm operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The firm mainly conducts its businesses in the China market.

Company Info

BURNING ROCK BIOTECH LTD-ADR

No. 5 Xingdao Ring Road North,, International Bio Island

Guangzhou GUANGDONG 510005

P: 8618501641666

CEO: Yusheng Han

Employees: 1138

Website: https://www.brbiotech.com/